Klaase J M, Kroon B B
Department of Surgery, Netherlands Cancer Institute, Amsterdam.
Br J Surg. 1990 Jan;77(1):60-1. doi: 10.1002/bjs.1800770121.
Melanoma frequently disseminates to the gastrointestinal tract, being found post-mortem in 60 per cent of patients with disseminated disease, while during life it is diagnosed in only 4 per cent. During the period 1981-87, 835 melanoma patients were referred and 30 developed complaints caused by gastrointestinal metastatic melanoma. Twenty-three patients were treated surgically. The interval between treatment of the primary melanoma and detection of intestinal involvement was a median of 34 months (range 2-87 months). In four patients recurrence in the gut was the first evidence of dissemination. Major complaints were nausea and vomiting, abdominal pain, signs of anaemia, and blood in the stools. Complications were bleeding (ten cases), ileus due to intussusception (five cases), bowel perforation (four cases) and cholecystitis (one case). The metastases, mainly localized in the small bowel, were removed by relatively simple procedures. Symptoms were reduced in 19 patients. Two patients died after operation: one from sepsis due to suture leakage, the other from pneumonia and a cerebrovascular accident. Of the remaining patients, 16 survived a median of 7.5 (range 0.7-32.0) months. Five patients are still alive 72, 72, 70, 7 and 2 months after the metastasectomy, three of whom are tumour-free. The actuarial 5-year survival of all patients is 19 per cent. These results support surgical intervention for patients with complaints and/or complications attributable to gastrointestinal metastatic melanoma.
黑色素瘤常转移至胃肠道,尸检发现60%的播散性疾病患者有胃肠道转移,而生前仅有4%被诊断出。在1981年至1987年期间,共收治835例黑色素瘤患者,其中30例出现胃肠道转移性黑色素瘤相关症状。23例患者接受了手术治疗。原发性黑色素瘤治疗至发现肠道受累的间隔时间中位数为34个月(范围2至87个月)。4例患者肠道复发是播散的首发证据。主要症状为恶心、呕吐、腹痛、贫血体征及便血。并发症包括出血(10例)、肠套叠所致肠梗阻(5例)、肠穿孔(4例)和胆囊炎(1例)。转移灶主要位于小肠,通过相对简单的手术即可切除。19例患者症状减轻。2例患者术后死亡:1例死于缝合口漏引起的败血症,另1例死于肺炎和脑血管意外。其余患者中,16例存活,中位生存期为7.5个月(范围0.7至32.0个月)。5例患者在转移灶切除术后72、72、70、7和2个月仍存活,其中3例无肿瘤。所有患者的5年精算生存率为19%。这些结果支持对有胃肠道转移性黑色素瘤相关症状和/或并发症的患者进行手术干预。